Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that Caesalpinia bonduc seed extracts significantly reduced prostate weight and improved prostate tissue morphology in Wistar rats with testosterone-induced benign prostatic hyperplasia.

This review covers recent advances in prostate cancer risk assessment, diagnosis, and treatment but does not report new clinical results; further studies on androgen deprivation therapy's cardiovascular risks are particularly noted.

This study found that age is the most significant risk factor for hemorrhagic cystitis after hematopoietic stem-cell transplantation, with additional risk factors including cyclophosphamide-based prophylaxis and, among male recipients, prostatic hyperplasia.

This article discusses androgenetic alopecia as a potential early marker for benign prostatic hyperplasia but reports no new clinical findings.

In this study, the ethanol extract of Zapoteca portoricensis stem significantly reduced markers of testosterone-induced benign prostate hyperplasia in male albino rats without harming liver and kidney function.

This study found that Thermobalancing therapy using Dr Allen's Device significantly improved symptoms and quality of life in men with benign prostatic hyperplasia, but larger prostate sizes may require longer treatment.

In this animal study, AGO (agomelatine) effectively alleviated testosterone-induced benign prostatic hyperplasia in rats by reducing oxidative stress and inflammation, indicating its potential as a therapeutic option for managing BPH through specific signaling pathways.

This study found that aqueous extract of Pueraria mirifica, when administered to a rat model, significantly reduced prostate weight, prostatic index, and serum dihydrotestosterone levels, while also improving prostate histomorphology, suggesting its potential as an anti-BPH treatment.

This dissertation found that finasteride reduced prostate volume by 6.3% and total serum PSA by 10.51% in young patients over one year.

The authors concluded that preoperative treatment with finasteride for a month effectively reduced perioperative bleeding and shortened hospital stays in patients undergoing transurethral resection of the prostate.

Low dose finasteride causes only minor changes in PSA levels in men over 50 with BPH.

This review discusses significant developments in prostate cancer risk assessment, diagnosis, and treatment, but reports no new clinical results; the authors emphasize the evolving importance of prognostic factors and treatment implications.

This review describes the roles of 5α-reductase isozymes in prostate development and pathology and reports no new clinical results.

In this study, corn silk extract treatment improved symptoms of testosterone-induced BPH by reducing specific mRNA expression and decreasing levels of 5α-R2, DHT, and PSA.

This study concluded that cyproterone acetate alone produced antiandrogenic effects on the female gerbil prostate, while ethinyloestradiol alone stimulated estrogenic activity, and their combination led to prostatic lesions.

In this study, researchers found that pregnant mice exposed to excessive androgen led to thinner ventricular walls and cardiac hypertrophy in offspring, suggesting that prenatal androgen exposure adversely affects cardiac health through reduced cardiomyocyte proliferation.

This study found that in men with benign prostatic hyperplasia, a 3-month treatment with a long-acting GnRH agonist significantly reduced intraprostatic DHT and 3α-diol levels by about 90% and testosterone by about 75%.

This review discusses phytotherapy options for managing benign prostatic hyperplasia, noting some herbal agents show promise in trials for mild-moderate symptoms but more evidence is needed for others.

This study found that 5-α reductase inhibitors do not significantly increase the risk of erectile dysfunction in men with benign prostatic hyperplasia or alopecia, although duration of benign prostatic hyperplasia may elevate risk.

This study suggests that the use of finasteride for benign prostate hyperplasia may increase the risk of osteoporosis diagnosis, particularly at higher doses.

This study found that long-term finasteride therapy in men with BPH worsened erectile dysfunction and reduced testosterone levels, while these effects were not observed with tamsulosin.

This study found that KH053, combining Panax ginseng and bee-pollen, significantly reduced prostate weight and DHT levels, inhibiting BPH development in a rat model.

This study suggests that using both finasteride and dutasteride may increase the risk of acute coronary syndrome in patients with benign prostate hyperplasia.

Using finasteride for hair loss or prostate issues does not significantly raise the risk of erectile dysfunction.

This study found that in men with benign prostatic hyperplasia, 5-alpha reductase inhibitors significantly increased the risk of gynecomastia and breast tenderness compared to placebo or alpha-blockers.

This study found that dutasteride is more cost-effective compared to finasteride for treating benign prostatic hyperplasia in Montenegro, justifying its funding by the national health insurance fund.

Certain gene variants may raise the risk of prostate enlargement, but taking NSAIDs could reduce this risk.

This article updates on the medical management of benign prostatic hyperplasia in companion animals and reports no new clinical findings; the authors discuss existing treatments.

This review discusses the role of 5α-reductase in prostate development and BPH, and reports no new clinical results; ongoing trials are exploring dual isozyme inhibitors for improved treatment efficacy.

This study demonstrates that patients with benign prostatic hyperplasia have a higher severity and frequency of male pattern baldness compared to a control group.